<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346437</url>
  </required_header>
  <id_info>
    <org_study_id>304386</org_study_id>
    <nct_id>NCT00346437</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardium Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardium Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4&#xD;
      is effective in improving exercise capacity measured by exercise treadmill testing, angina&#xD;
      functional class, patient symptoms, quality of life, and cardiovascular outcomes. Two doses&#xD;
      will be studied, 2.87 x 10(8) and 2.87 x 10(9) viral particles, to evaluate the dose-response&#xD;
      of Ad5FGF-4. Short-term and long-term safety of Ad5FGF-4 will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in treadmill exercise duration from baseline</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a =&gt;30% increase in exercise duration compared to baseline</measure>
    <time_frame>4 weeks, 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with and time to coronary events or all-cause death</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treadmill exercise duration compared to baseline</measure>
    <time_frame>4 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to 1 mm ST segment depression during ETT compared to baseline</measure>
    <time_frame>4 weeks, 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to angina onset during ETT compared to baseline</measure>
    <time_frame>4 weeks, 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CCS class compared to baseline</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly frequency of anginal attacks compared to baseline</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly PRN nitroglycerin use compared to baseline</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (SAQ, DASI, SF-36, EQ-5D) compared to baseline</measure>
    <time_frame>4 weeks, 12 weeks, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad5FGF-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad5FGF-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Ad5FGF-4 vs. Placebo</intervention_name>
    <description>Intracoronary infusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 30-75 years, male or female, with coronary artery disease&#xD;
&#xD;
          -  Patients over 50 years of age agree to undergo sigmoidoscopy, unless they have&#xD;
             undergone such an exam or colonoscopy within the preceding 36 months with negative&#xD;
             findings&#xD;
&#xD;
          -  CCS angina Class 2 to 4&#xD;
&#xD;
          -  Stable angina for =&gt;4 weeks despite antianginal drug treatment, and who are able to&#xD;
             exercise for at least 3 minutes but no more than 10 minutes on the first qualifying&#xD;
             baseline ETT and no more than 12 minutes on the last qualifying baseline ETT using the&#xD;
             modified Balke exercise protocol&#xD;
&#xD;
          -  LVEF =&gt;30% by echocardiography, LV angiogram, or a MUGA scan undertaken within the&#xD;
             preceding 12 months&#xD;
&#xD;
          -  Classic angina or angina equivalent associated with =&gt;1mm ST segment depression&#xD;
             (horizontal or down sloping) at least in the first qualifying ETT. The variability in&#xD;
             exercise duration (time to grade 3/4 angina or angina equivalent) does not vary by &gt;&#xD;
             20% in 2 consecutive tests&#xD;
&#xD;
          -  Single, double, or triple vessel coronary artery disease. Patients with 3 vessel&#xD;
             disease should have at least 1 proximal major vessel or graft with &lt;70% stenosis&#xD;
&#xD;
          -  Patients who do not require immediate PTCA or CABG surgery&#xD;
&#xD;
          -  Provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  CCS Class 1 angina&#xD;
&#xD;
          -  Patients in whom ECG evidence of exercise induced myocardial ischemia is difficult to&#xD;
             detect&#xD;
&#xD;
          -  Intercurrent illness which may interfere with the ability to perform the ETT&#xD;
&#xD;
          -  Untreated life-threatening ventricular arrhythmias&#xD;
&#xD;
          -  Left main coronary artery stenosis =&gt;70%, unless bypassed with a patent graft&#xD;
&#xD;
          -  Coronary artery bypass surgery within the past 6 months, unless those grafts are&#xD;
             closed&#xD;
&#xD;
          -  In situ arterial CABG other than the RIMA or LIMA, unless it is 100% occluded&#xD;
&#xD;
          -  Myocardial infarction within the last 8 weeks&#xD;
&#xD;
          -  CHF (NYHA class IV) despite treatment&#xD;
&#xD;
          -  Angioplasty within the previous 6 months&#xD;
&#xD;
          -  Prior transmyocardial laser revascularization&#xD;
&#xD;
          -  Enhanced external counterpulsation (EECP) within 12 weeks prior to study entry&#xD;
&#xD;
          -  Coronary ostial stenosis that precludes adequate catheter engagement in any target&#xD;
             vessel&#xD;
&#xD;
          -  Coronary artery to venous communications which bypass the coronary capillary bed&#xD;
&#xD;
          -  Heparin associated thrombocytopenia (HIT)&#xD;
&#xD;
          -  Moderate to severe nonproliferative or proliferative retinopathy from any cause (ETDRS&#xD;
             Score &gt; 35), clinically significant macular edema, or previous panretinal&#xD;
             photocoagulation therapy&#xD;
&#xD;
          -  History of malignant neoplasms (except superficial basal cell skin carcinoma) within&#xD;
             the past 10 years&#xD;
&#xD;
          -  Malignant tumors or abnormal cancer screening tests suspicious for cancer, or patients&#xD;
             in whom screening exams indicate possible occult malignancy, unless malignancy has&#xD;
             been ruled out&#xD;
&#xD;
          -  Family history of colon cancer in any first-degree relative, unless the patient has&#xD;
             undergone a colonoscopy within the past 12 months with negative findings&#xD;
&#xD;
          -  Elevated PSA level (unless prostate cancer has been excluded)&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Hepatic disease or those who are positive for hepatitis B or C, or whose SGPT is &gt; 2&#xD;
             times the upper limit of normal range, or whose serum bilirubin is &gt; 2 mg/dL.&#xD;
&#xD;
          -  Proteinuria =&gt; 2+ unless all other renal parameters are within normal limits.&#xD;
&#xD;
          -  Creatinine clearance &lt; 45 ml/min&#xD;
&#xD;
          -  Platelet count less than 130 x 10(3)/microL&#xD;
&#xD;
          -  WBC count less than 3.0 x 10(3)/microL&#xD;
&#xD;
          -  Patients who are known to be immunosuppressed and/or are receiving chronic&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Female patients of childbearing potential. Male patients who do not agree to use birth&#xD;
             control (condom) for a period of 8 weeks following study product administration&#xD;
&#xD;
          -  Investigational drug therapy within 30 days of treatment&#xD;
&#xD;
          -  Patients who have received any gene therapy product or angiogenic growth factor&#xD;
             protein product&#xD;
&#xD;
          -  Underlying disease(s) other than CAD resulting in a life expectancy of less than 1&#xD;
             year&#xD;
&#xD;
          -  Any clinical abnormality or social circumstance that puts successful completion of the&#xD;
             trial in doubt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Foster, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cardium Therapeutics, 12255 El Camino Real #250, San Diego, CA 92130, (858) 436-1000</affiliation>
  </overall_official>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>June 28, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angina</keyword>
  <keyword>FGF-4</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>adenovector</keyword>
  <keyword>growth factor</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

